Dec 14, 2020

ApiJect Systems Appoints General Counsel & Chief Compliance Officer James A. Garrett joins the company with extensive legal and strategic business expertise. Contract Pharma Staff12.14.20 ApiJect Systems Corp. , a global injectable platform technology company that revolutionizes how medicines and vaccines are filled, finished, and delivered, has appointed James A. Garrett as its new general counsel and chief compliance officer. This appointment took effect December 7, 2020. Garrett joins ApiJect with extensive legal and strategic business expertise. Since 2012 he served in executive leadership roles at NuVasive Inc., a global public company dedicated to advancing the adoption of less invasive surgery through procedural integration and the use of enabling technologies. As senior vice president for Business and Quality Systems, as well as Government & Regulations Strategy (2018-2020) he delivered strategic direction across multiple business units to support, among other things, the organization's sterile packaging and device traceability solutions and quality management efforts. He previously served NuVasive as vice president, chief risk & compliance officer (2017-2019), and vice president, Associate General Counsel (2012-2017). In these capacities, Garrett expanded risk management capabilities within the legal department, provided strategic management of global litigation, and actively led an extensive network of legal counsel, experts and advisors. From 2001-2010, Garrett practiced law across diverse industries including retail, manufacturing, and biological sciences/healthcare with the firms Brobeck Phleger & Harrison LLP, (Associate, 2001-2003), Pillsbury Winthrop Shaw Pittman LLP, (Senior Associate, 2003-2008), and DLA Piper LLP, (Of Counsel, 2008–2010). He holds a J.D. from the University of San Diego School of Law. Garrett assumes responsibilities from Magdalena Fincham, who served as ApiJect's counsel for Intellectual Property before stepping into the role of interim general counsel. Through her private practice, Fincham will continue to support ApiJect's intellectual property strategy and activities.